BioNTech SE Operating Income 2011-2026 | BNTX

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income BioNTech SE

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	15.3 B	-82.4 M	-182 M	-53.9 M	-61.3 M	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
15.3 B	-182 M	2.98 B

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Can-Fite BioPharma Ltd. CANF	-9.95 M	$ 2.92	-	$ 4.81 M	Israel
AlloVir ALVR	-46.2 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Precision BioSciences DTIL	-43.7 M	$ 6.67	-	$ 25.6 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Esperion Therapeutics ESPR	60.3 M	$ 2.17	-	$ 451 M	USA
Evogene Ltd. EVGN	-31 M	$ 0.81	-	$ 27.9 M	Israel
Forte Biosciences FBRX	-70.7 M	$ 35.09	-	$ 454 M	USA
Amphastar Pharmaceuticals AMPH	140 M	$ 20.37	-	$ 952 M	USA
Galectin Therapeutics GALT	-20.1 M	$ 2.3	-	$ 147 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Grifols, S.A. GRFS	595 M	$ 8.21	-	$ 6.83 B	Spain
GT Biopharma GTBP	-12.4 M	$ 0.37	-	$ 2.04 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Halozyme Therapeutics HALO	469 M	$ 67.82	-	$ 8.13 B	USA
Celldex Therapeutics CLDX	-287 M	$ 32.24	-	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	23.5 M	$ 1.4	-	$ 360 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	-71.1 M	$ 4.08	-	$ 436 M	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	-12.2 M	$ 24.21	-	$ 3.08 B	USA
AIkido Pharma AIKI	-55.7 M	-	1.93 %	$ 17.4 M	USA
Hoth Therapeutics HOTH	-12.4 M	$ 0.52	-	$ 7.18 M	USA
Autolus Therapeutics plc AUTL	-271 M	$ 1.49	-	$ 397 M	Britain
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	10.2 M	-	1083.1 %	$ 745 M	USA
ImmuCell Corporation ICCC	1.65 M	$ 7.08	-1.6 %	$ 63.9 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-7.83 M	$ 2.55	-	$ 16 M	USA
Incyte Corporation INCY	1.51 B	$ 96.07	-	$ 18.8 B	USA
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain